The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Lantus (insulin glargine) and a possible increased risk of cancer. Lantus is a long-acting ...
Lantus (insulin glargine) is a brand-name subcutaneous injection that’s prescribed for diabetes. It’s used in adults and some children. The cost of the drug with and without insurance can depend on ...
The FINANCIAL — Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced on September 20 results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results